RNAC: Cartesian Therapeutics Inc Net earnings per share (EPS TTM)

Public company logo of Selecta Biosciences (RNAC)

Cartesian Therapeutics (RNAC) develops RNA-based drugs to combat cancer and autoimmune pathologies, diversifying risks across various disease types. The company's net income per share over 12 months settled at -4.99, providing a basis to assess the efficiency of its capital management. Despite high production costs and fierce scientific competition, the brand maintains strong authority and investor confidence.

RNAC (Cartesian Therapeutics) Net earnings per one share for the last twelve months history from 02/21/2024 to 11/10/2026

Selecta Biosciences - analytical breakdowns and key metrics (RNAC)

- share price and expert price forecast:
Stock Quotes Cartesian Therapeutics|RNAC - Fair Value Consensus
- market capitalization information:
Market Capitalization Cartesian Therapeutics, Inc.|RNAC - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share Cartesian Therapeutics|RNAC - Total Stockholders' Equity|Market Value to Book Value Ratio selectabio.com|RNAC - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Cartesian Therapeutics|RNAC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Cartesian Therapeutics Inc|RNAC - Aggregate Debt Obligations|Debts to Book Capitalization Cartesian Therapeutics, Inc.|RNAC - Long-Term Indebtedness|Company Short-Term Debts Cartesian Therapeutics|Quick Liquidity selectabio.com
- net income and valuation multiples indicators:
RNAC - Company Profit|Projected Future Earnings Cartesian Therapeutics|RNAC - Market Cap to Earnings|Projected Price to Earnings Cartesian Therapeutics, Inc.|RNAC - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Cartesian Therapeutics, Inc.|RNAC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Cartesian Therapeutics|RNAC - Earnings per share for the trailing year|Quarterly EPS earnings growth selectabio.com|RNAC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Cartesian Therapeutics
General company analysis:Cartesian Therapeutics (RNAC)
Mass-produced product of Selecta Biosciences Inc.

Annual net income per share reflects the actual earnings of a single security holder, excluding temporary market fluctuations. By analyzing the TTM net income per share, an investor assesses the capital allocation efficiency of Cartesian Therapeutics (RNAC), where financial stability is bolstered by the implementation of sustainable ESG standards and strict adherence to biosafety protocols in the development of innovative gene therapies.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (sana.com)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics, Inc.|CLLS (Cellectis SA) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Caribou Biosciences, Inc CRBU|Earnings per share for the last twelve months Instil Bio, Inc. (TIL)|Earnings per share for the last twelve months GNTA (genenta.com)|Earnings per share for the last twelve months Century Therapeutics, Inc. IPSC|Jasper Therapeutics Inc - Earnings per share for the last twelve months|SNTI: Net earnings per share for the last 12 months|Earnings per share for the trailing year ADAP (Adaptimmune)|CERO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Alaunos Therapeutics, Inc. TCRT|ACHL (Achilles Therapeutics PLC) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CARGO Therapeutics Inc. CRGX|Earnings per share for the last twelve months Poseida (PSTX)|2seventy bio, Inc - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell Biotechnologies)